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OBJECTIVES: To compare patient management and outcome during the first 
and second waves of the coronavirus 2019 pandemic.
DESIGN: Single-center prospective cohort study.
SETTING: Tertiary-care University Hospital.
PATIENTS: All adult patients admitted in either the first (from March 15 to May 
15, 2020) or second (from October 1 to November 30, 2020) wave of corona-
virus disease 2019.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Primary outcome was 30-day mor-
tality. During the second wave of the coronavirus disease 2019 pandemic, 33 
patients (4.8%) were transferred due to overcrowding and excluded from anal-
ysis. There were 341 (first wave of the coronavirus disease 2019 pandemic) and 
695 (second wave of the coronavirus disease 2019 pandemic) coronavirus di-
sease 2019 patients admitted to the hospital, with median age first wave of the 
coronavirus disease 2019 pandemic as 68 (57–80) and second wave of the 
coronavirus disease 2019 pandemic as 71 (60–80) (p = 0.15), and similar admis-
sion severity. For the first wave of the coronavirus disease 2019 pandemic versus 
second wave of the coronavirus disease 2019 pandemic, 30-day mortality was 
74/341 (22%) and 98/662 (15%) (p = 0.007). In the ward, 11/341 (3.2%) and 
404/662 (61%) received dexamethasone (p < 0.001); 6/341 (2%) and 79/662 
(12%) received high-flow nasal oxygen (p < 0.0001); 2/341 (0.6%) and 88/662 
(13.3%) received remdesivir (p < 0.0001); 249/341 (73%) and 0/662 (0%) re-
ceived hydroxychloroquine (p < 0.0001); and 87/341 (26%) and 128/662 (19%) 
(p = 0.024) patients were transferred to ICU. On ICU admission, median 
Sequential Organ Failure Assessment was 6 (3–7) and 4 (3–6) (p = 0.02). High-
flow nasal oxygen was given to 16/87 (18%) and 102/128 (80%) (p < 0.001); 
69/87 (79%) and 56/128 (44%) received mechanical ventilation (p < 0.001) 
with durations 17 days (10–26 d) and 10 days (5–17 d) (p = 0.01). Median ICU 
length of stay was 14 days (5–27 d) and 6 days (3–11 d) (p < 0.001). Finally, 
16/87 (18%) and 8/128 (6%) received renal replacement therapy (p = 0.0055); 
and 64/87 (74%) and 51/128 (40%) needed vasopressor support (p < 0.001).
CONCLUSIONS: The main therapeutic changes between the first wave of the 
coronavirus disease 2019 pandemic and the second wave of the coronavirus di-
sease 2019 pandemic were use of steroids, unrestrictive use of high-flow nasal 
oxygen for hypoxemic patients, and transfer of patients to other geographic areas 
in the case of ICU overcrowding. These changes were associated with a de-
crease in 30-day mortality, ICU admission, and organ support.
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During the coronavirus disease 2019 (COVID-2019) pandemic, several questions on patient management and therapeutic options arose 
concerning care of moderate and severe COVID-19 
patients requiring oxygen support or mechanical ven-
tilation (MV) (1).
Initially, steroids were not recommended, because it 
could decrease virus clearance, as suggested in other 
viral infections (2, 3). However, single-center studies, 
later confirmed by the Recovery study, demonstrated 
a significant decrease in mortality in patients requir-
ing oxygen support or MV when treated by dexameth-
asone (4). A further meta-analysis confirmed these 
results (5). In addition, remdesivir was also recom-
mended in patients with oxygen support in the first 
and subsequent second waves of the COVID-19 pan-
demic (6). In contrast, hydroxychloroquine was not 
recommended by the time of the second wave due to 
the lack of evidence (7). Finally, high-flow nasal ox-
ygen (HFNO) was initially suspected to aerosolize 
severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) in room air (8), and its use was limited 
to flows under 30 L/min. However, later studies in the 
first wave showed the risk of aerosolization was limited 
even when using HFNO at flow as high as 60 L/min 
(9). All these results show substantial, progressive, and 
evidence-driven modification in the management of 
COVID-19 in our hospital, and internationally (7, 10).
This study assesses the impact of these changes in 
patient management on patient outcomes.
MATERIALS AND METHODS
Study Design and Participants
This prospective single-center cohort study was 
conducted at the University Hospital of Liege. The 
Ethics Committee of the University Hospital of Liege 
(Comité d’éthique hospitalo-universitaire de Liège 
[707]) reviewed the study and approved it (Reference: 
2021/032). Informed consent was not required, be-
cause the study did not modify patients’ management 
and the data were anonymously collected.
All adult patients admitted to the University Hospital 
of Liege for acute respiratory failure due to SARS-CoV-2 
pneumonia diagnosed with a positive polymerase chain 
reaction (PCR) for SARS-CoV-2 in nasal swab or other 
respiratory samples during the 5 days of their admis-
sion in the hospital or in the 14 days before admission 
were included. The detection of SARS-CoV-2 was per-
formed by reverse transcription polymerase chain re-
action using the Cobas SARS-CoV-2 assay (Roche, 
Switzerland) for the detection of the ORF1ab and E 
genes. The results were reported as cycle thresholds in 
order to give an approximation of the viral load.
Patients were admitted in either the first wave of 
COVID-19 from March 15 to May 15, 2020 (W1), or 
the second wave from October 1 to November 30, 2020 
(W2) (11). Patients with positive SARS-CoV-2 PCR and 
primarily hospitalized for scheduled or urgent surgery 
were excluded. The hospital expanded its total ICU ca-
pacity from 58 to 68 beds during W1 and 71 beds dur-
ing W2, with 10 to 12 beds dedicated to non-COVID-19 
critically ill patients. In the ward, 196 beds were dedi-
cated to COVID-19 patients during the two waves.
Procedure
During W1, Belgian public health services did not 
recommend the use of steroids because of the risk of 
decreasing the clearance of the SARS-CoV-2, and rec-
ommend hydroxychloroquine treatment in COVID-19 
patients. Antibiotic treatment was started in all 
COVID-19 patients and stopped after 48 hours if PCR 
multiplex on respiratory samples revealed no pulmo-
nary infection. Due to the high potential risk of aero-
solization in room air and monitoring needs, patients 
did not receive HFNO in the ward. All patients requir-
ing oxygen support over 15 L/min with reservoir mask 
and with respiratory rate above 30/min were admitted 
to ICU. Once in ICU, patients received HFNO with a 
maximum flow of 30 L/min, because it was believed 
the risk of aerosolization was too high above this 
value. ICU discharge was allowed when patients were 
weaned from HFNO and required oxygen supply only 
by normal flow.
During W2, dexamethasone in all COVID-19 
patients under oxygen support or MV was started early 
at 6 mg/d for 10 days. Patients requiring oxygen sup-
port, but not MV, and in whom COVID-19 symptoms 
started less than 5 days previously received IV remde-
sivir with a starting dose of 200 mg and then a daily 
dose of 100 mg a day for 5–10 days. Antibiotics were 
started for suspected bacterial infections, based on the 
presence of parenchymatous condensation on compu-
terized tomography scanner of the lung, leucocytes and 
positive culture in the endotracheal aspirate, or in the 
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sputum in nonintubated patients, or evidence of septic 
shock. HFNO was used in the ward under appropriate 
monitoring and in the ICU at flows up to 60 L/min. 
Patients with refractory hypoxemia (Pao2 < 60 mm 
H2O) under HFNO or mild hypoxemia with a respi-
ratory rate above 30/min were admitted to ICU. Once 
in ICU, patients could receive noninvasive ventilation 
and could benefit from prone position while in sponta-
neous ventilation. Patients were discharged from ICU 
when weaned from MV, regardless they were still on 
HFNO or on normal-flow oxygen supply.
During W2, to minimize risk of severe ICU over-
crowding, patients were regularly transferred to other 
Belgian areas or to Germany, provided they had been 
in a stable condition for more than 48 hours, preferably 
under MV, to ensure safe transport.
During both W1 and W2, all personnel protec-
tion measures against aerosolization risk remained in 
force, as well as COVID-19 patient isolation measures. 
Enoxaparin was given at a dosage of 1 mg/kg once a 
day, except in the case where a full anticoagulation was 
clearly requested by another pathology.
Major differences in the clinical management of 
COVID-19 patients in the first and second wave are 
depicted in Figure 1.
Data Collection
We prospectively collected data on hospital admis-
sion, during hospitalization, on ICU admission, and 
during the ICU stay. On hospital admission, demo-
graphic data, comorbidities, SARS-CoV-2 viral load, 
physiologic, and biological values were collected. 
During hospitalization, the use of drugs oriented 
against COVID-19 (hydroxychloroquine, remdesivir, 
and steroids), use of HFNO, and date of ICU admis-
sion were collected. On ICU admission, patients’ char-
acteristics, the same physiologic and biological values 
as on hospital admission, and the Sequential Organ 
Failure Assessment (SOFA) score were collected. 
Characteristics of patients transferred to other hospi-
tals were also collected on ICU admission.
During the first week of ICU stay, the highest creati-
nine, bilirubin, C-reactive protein (CRP), and d-dimer 
values, along with the lowest platelet count, were col-
lected. Over the entire ICU stay, data on the use of 
enoxaparin, antibiotic, vasopressors, renal replacement 
therapy (RRT), extracorporeal membrane oxygenation, 
the delay between ICU admission and intubation, du-
ration of HFNO and MV, the length of ICU stay, and 
28-day ICU-free and ventilator-free days were collected.
Figure 1. Clinical management of coronavirus disease 2019 patients during the first and second waves of the pandemic. HFNO = high-
flow nasal oxygen, RR = respiratory rate.
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Outcome
The primary outcome was 30-day mortality. Secondary 
outcomes were: 30-day mortality of ICU patients, ad-
mission to ICU, length of ICU stay, delay between ICU 
admission and intubation, use and duration of MV, 
28-day ICU-free days and ventilator-free days; use and 
duration of HFNO, vasopressor support, RRT, and risk 
factors of mortality.
Statistical Methods
Quantitative variables were reported as median (Q1–
Q3) and categorical variables as number (%). Kruskal-
Wallis and Fisher exact tests were used as appropriate. 
Cox regression models were used to assess risk factors 
of mortality. Hazard ratio and 95% CIs were reported. 
All the variables with p < 0.1 were selected for the mul-
tivariate model. A value of p < 0.05 was considered sig-
nificant. Overall survival is presented by Kaplan-Meier 
curves. Missing data were not replaced. Calculations 
were performed using SAS (version 9.4, SAS insti-
tute, Cary, NC) and R (version 3.6.2, Foundation for 
Statistical Computing, Vienna, Austria). All statistical 
analyses were done by the Biostatistics and Medico-
Economic Information Department of the University 
Hospital of Liege (Liege, Belgium).
RESULTS
During W1 and W2, respectively, 341 and 695 patients 
fulfilling all the inclusion criteria were hospitalized 
for COVID-19. Thirty-three W2 patients (4.8%) were 
transferred to other hospitals due to local overcrowd-
ing and excluded from analysis (Fig. 1, Supplement 
Digital Content, http://links.lww.com/CCX/A643). 
Their severity on ICU admission was the same as 
patients who remained (Table 1, Supplement Digital 
Content, http://links.lww.com/CCX/A642).
On hospital admission, demographic data, comor-
bidities, physiologic and biological data, and viral load 
were the same in W1 and W2, except ferritin and respi-
ratory rate, which were slightly but significantly higher 
in W1 patients (Table  1). Missing viral load data in 
Table 1 is due to some tests being performed outside 
the hospital or not reported in the patient’s medical file 
by the laboratory. During W1, 11/341 patients (3.2%) 
were treated with dexamethasone growing to 404/662 
patients (61%) in W2 (p < 0.0001). Dexamethasone was 
started 14 days (13–22 d) and 1 day (0–1 d) after hospital 
admission in W1 and W2, respectively (p < 0.0001). 
Remdesivir was given in 2/341 W1 patients (0.6%) and 
88/662 W2 patients (13.3%) (p < 0.0001), starting at 
16 days (11–21 d) and 1 days (0–1 d) after admission 
(p = 0.009). Hydroxychloroquine was given in 249/341 
W1 patients (73%) and 0/662 W2 patients (0%) (p < 
0.0001). During W1, 87/341 patients (26%) were trans-
ferred from the ward to ICU, whereas 128/662 (19%) 
during W2 (p = 0.024) (Table 1).
In the ward, 6/341 W1 patients (2%) and 79/662 W2 
patients (12%) received HFNO (p < 0.0001) for 4 days 
(2—6 d) and 3 days (2–7 d) (p = 0.97). Two of six W1 
patients (33%) and 34/79 W2 patients (43%) receiving 
HFNO in the ward were transferred to ICU (p = 0.64). 
The two W1 patients who were transferred to the ICU 
required immediate intubation and MV.
During W1 and W2, 87/341 (26%) and 128/662 
(19%) (p = 0.024) patients were admitted to ICU (Fig. 1, 
Supplement Digital Content, http://links.lww.com/
CCX/A643). On ICU admission, median SOFA score 
was 6 (3–7) in W1 and 4 (3–6) in W2 (p = 0.02), but 
Pao2/Fio2 ratio was 108 (84–134) and 91 (71–116), re-
spectively (p = 0.027) (Table  2). On ICU admission, 
lymphocyte count, CRP, d-dimer, and bilirubin values 
were statistically significantly higher in W1 than in W2 
patients (Table 2).
During the first week of ICU stay, CRP, creatinine, 
and bilirubin reached higher maximum values in W1 
than W2 patients (Table  3). During ICU stay, 16/87 
(18%) and 102/128 (80%) received HFNO (p < 0.0001) 
with a flow of 36 L/min (30–50 L/min) and 50 L/min 
(46–60 L/min) (p < 0.001) and 69/87 (79%) and 56/128 
(44%) were mechanically ventilated (p < 0.001), re-
spectively. The delay between ICU admission and in-
tubation was longer in W2 than in W1. Median length 
of ICU stay, median 28-day ICU-free days, and median 
MV duration were shorter in W2 than W1 (Table 3). 
Finally, fewer W2 patients received RRT, antibiotic, 
and vasopressors (Table 3).
During W1 and W2, 1/57 (2%) and 46/90 (51%) 
patients were discharged from ICU while on HFNO 
(p < 0.001).
During W1 and W2, 30-day mortality was 74/341 
(22%) and 99/662 (15%) (p = 0.007) and 30-day ICU 
mortality was 25/87 (29%) and 31/128 (24%) (p = 0.61), 
respectively. The overall survival is presented by 
Kaplan-Meier curves (Fig. 2, Supplement Digital 
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Content, http://links.lww.com/CCX/A644, and Fig. 3, 
Supplement Digital Content, http://links.lww.com/
CCX/A645). In ICU, 18/25 (72%) and 24/31 (77%) 
patients died while a withholding or a withdrawing 
therapy has been previously decided, respectively, dur-
ing W1 and W2 (p = 0.76). Cox regression models 
showed that independent risk factors for 30-day mor-
tality of hospitalized patients were: W1, higher age, 
higher CRP and serum creatinine values, and lower 
platelet count and Spo2 values on hospital admission 
(Table  4). Cox regression models showed that in-
dependent risk factors for 30-day mortality of ICU 
patients were: higher age, SOFA score on ICU admis-
sion, and lower lymphocyte count on ICU admission 
(Table 5).
DISCUSSION
In our single tertiary-care hospital, we could compare 
two cohorts of consecutive patients during the first 
TABLE 1. 
Patients Characteristics on Hospital Admission, Evolution and Treatment During the First 
and the Second Waves of Coronavirus Disease 2019 Pandemic
Variables








Age (yr) 68 (57–80) 341 71 (60–80) 662 0.15
Body mass index (kg/m2) 27.2 (24–31) 257 27.0 (24–31) 509 0.054
Sex (male) 200 (59%) 341 386 (58%) 662 0.92
Chronic kidney disease 37 (10.9%) 341 66 (10%) 662 0.66
Diabetes 125 (37%) 341 283 (43%) 662 0.063
Hypertension 181 (53%) 341 322 (49%) 662 0.18
Bilirubin (mg/dL) 0.68 (0.5–0.97) 336 0.64 (0.48–0.9) 640 0.14
C-reactive protein (mg/L) 81.8 (33.6–166) 339 78.2 (29.0–146) 645 0.15
Creatinine (mg/dL) 0.99 (0.81–1.35) 338 0.99 (0.77–1.38) 644 0.68
d-dimer (ng/mL) 924 (540–1,782) 297 1,020 (576–2,004) 552 0.13
Ferritin (µg/L) 1,003 (531–2,329) 77 743 (327–2,017) 189 0.041
Lymphocyte count (103/mm3) 0.94 (0.66–1.23) 337 0.90 (0.63–1.31) 644 0.51
Platelet count (103/mm3) 195 (155–263) 337 209 (161–274) 644 0.15
Spo2 (%) 94 (90–96) 340 93 (90–96) 658 0.53
Respiratory rate (/min) 22 (19–29) 325 20 (18–25) 575 0.0003
Heart rate (/min) 90 (79–103) 341 88 (76–101) 662 0.15
Mean arterial pressure (mm Hg) 94.0 (86.0–103) 341 94.3 (83.6–105) 662 0.48
Viral load (cycle threshold) 27.5 (23–31) 279 26.5 (21–32) 454 0.91
Hyrdoxychloroquine 249 (73%) 341 0 (0%) 662 <0.0001
Remdesivir 2 (0.6%) 341 88 (13.3%) 662 <0.0001
Dexamethasone 11 (3.2%) 341 404 (61%) 662 <0.0001
Transfer in ICU 87 (26%) 341 128 (19%) 662 0.024
30-d mortality 74 (22%) 341 99 (15%) 662 0.007
Age of deceased patients (yr) 79.5 (71–86) 74 82 (74–88) 99 0.069
COVID-19 = coronavirus disease 2019.
Quantitative variables are reported as median (Q1–Q3) and categorical variables as number (%). Kruskal-Wallis and Fisher exact tests 
are used as appropriate.
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two waves of the COVID-19 pandemic in Belgium. 
Our results showed W2 patient management drasti-
cally differed from W1. W2 patients were more fre-
quently treated with dexamethasone and remdesivir, 
and received HFNO more frequently and for longer, in 
both the ward and ICU. No patients received hydroxy-
chloroquine during W2. Due to the local risk of ICU 
overcrowding, during W2, 33 patients were transferred 
to other hospitals. All these modifications in patient 
management were associated with a decrease in: the 
number of patients admitted to ICU from the ward, 
ICU length of stay, the number of patients under MV, 
the length of MV, RRT, vasopressor use, antibiotic use, 
and biological inflammatory syndrome on ICU admis-
sion and during ICU stay. This global change in patient 
management during W2 was also associated with a de-
crease in 30-day mortality.
Changes in patient management strategy from W1 
to W2 were justified by several studies during W1 (7). 
In particular, during W1, Belgian and international 
recommendations limited HFNO to the ICU and a 
rate of 30 L/min. Similarly, Belgian and international 
recommendations restricted steroid use in W1, and 
hydroxychloroquine was given to almost all COVID-19 
patients (2, 10, 12). In contrast, the Recovery study 
and subsequent meta-analysis led to early steroid use 
in W2 (4, 5). Furthermore, remdesivir was also used 
for selected patients based on the results of Beigel et 
al (6), and hydroxychloroquine use was discontinued 
due to lack of evidence (7, 13, 14). HFNO use was 
expanded to the wards and a 60 L/min limit author-
ized (9), where personal protection equipment and 
COVID-19 patient isolation measures were used to re-
duce aerosol contamination risk (15). Finally, to avoid 
severe ICU overcrowding, regular patient transfers to 
other hospitals were introduced, where overcrowding 
and strained ICU capacity is associated with increased 
ICU mortality (16).
TABLE 2. 
Patients Characteristics on ICU Admission During the First and second Waves of Corona-
virus Disease 2019 Pandemic
Variables








Age (yr) 65 (54–71) 87 67.0 (59.5–74.0) 128 0.078
Body mass index (kg/m2) 30.8 (26.3–34.6) 80 28.1 (25.1–32.2) 117 0.0056
Chronic kidney disease 19 (21.8%) 87 25 (19.5%) 128 0.68
Diabetes 43 (49.4%) 87 59 (46%) 128 0.63
Hypertension 40 (46%) 87 88 (72.1%) 122 0.0008
Sequential Organ Failure  
Assessment score
6 (3–7) 85 4 (3–6) 120 0.021
C-reactive protein (mg/L) 173 (113–244) 86 111 (63.9–197) 127 0.0005
Bilirubin (mg/dL) 0.75 (0.54–1.13) 86 0.65 (0.48–0.89) 126 0.036
Creatinine (mg/dL) 0.97 (0.78–1.36) 86 0.87 (0.70–1.23) 127 0.11
d-dimer (ng/mL) 1,895 (922–4,717) 67 1,280 (603–2,043) 118 0.0018
Ferritin (µg/L) 1,968 (746–4,461) 40 1,327 (612–2,725) 83 0.21
Lymphocyte count (103/mm3) 0.80 (0.56–1.11) 86 0.66 (0.42–0.96) 127 0.010
Platelet count (103/mm3) 205 (163-268) 86 233 (159–305) 127 0.14
Pao2/Fio2 (mm Hg) 108 (84.4–134) 56 91.2 (70.5–116) 80 0.028
Mean arterial pressure (mm Hg) 66.3 (59.7–73.7) 87 71.0 (64.5–77.8) 128 0.027
COVID-19 = coronavirus disease 2019.
Quantitative variables are reported as median (Q1–Q3) and categorical variables as number (%). Kruskal-Wallis and Fisher exact tests 
are used as appropriate.
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These “bundles” of major patient management 
modifications were associated with a series of cascad-
ing changes. Patients were admitted to the ICU later 
or less often, and had a shorter stay. Consequently, W2 
patients transferred to the ICU had more severe respi-
ratory dysfunction on ICU admission, whereas their 
inflammatory syndrome was less severe. Table 1 shows 
biological values were the same on hospital admission 
during W1 and W2. However, Table 2 shows on ICU 
admission, lymphocytes, CRP, d-dimers, and bilirubin 
were lower during W2 than W1. Table 3 shows during 
the first week of ICU stay, CRP, bilirubin, and creati-
nine values increased less during W2 than W1. Once 
in the ICU, HFNO duration was longer and MV was 
TABLE 3. 
Characteristics of the ICU Stay During the First and Second Waves of the Coronavirus 
Disease 2019 Pandemic
Variables
First Wave of  




Second Wave  




Hospitalization LOS (d) 8 (5–15) 341 8 (5–13) 662 0.030
Hospitalization LOS, ICU patients (d) 22 (11–39) 87 13 (9–23) 128 0.0028
30-d ICU mortality 25 (29%) 87 31 (24%) 128 0.61
LOS in ICU (d) 13.8 (5.1–26.8) 87 6.3 (2.8–11.0) 128 <0.0001
ICU-free days on day 28 0 (0–14) 87 17.5 (0.0–23.0) 128 <0.0001
MV 69 (79%) 87 56 (44%) 128 <0.001
MV (d) 17 (10–26) 69 10.0 (5.0–17.5) 56 0.010
MV-free days on day 28 1 (0–12) 69 0.5 (0.0–19.0) 56 0.32
Prone position (number of patients) 55 (63%) 87 57 (45%) 128 0.007
Prone position (d) 3 (0–6) 87 0 (0–3) 128 0.0018
HFNO in ICU 16 (18%) 87 102 (80%) 128 <0.0001
HFNO in ICU (d) 2 (1–2) 5 5 (3–7) 59 0.0027
Delay between MV and ICU admission (d) 0.08 (0.02–0.78) 69 1.12 (0.04–3.05) 56 0.0019
Renal replacement therapy 16 (18.4%) 87 8 (6.3%) 128 0.0055
Norepinephrine use 64 (73.6%) 87 51 (39.8%) 128 <0.0001
Enoxaparin use 83 (95.4%) 87 117 (91.4%) 128 0.26
Enoxaparin daily dose (mg) 70 (51–87) 87 76 (60–96) 128 0.082
Extracorporeal membrane oxygenation 2 (2.3%) 87 3 (2.3) 125 0.98
Antibiotic use 78 (89.7%) 87 85 (66.4%) 128 <0.0001
C-reactive protein (mg/L) (max) 284.8 (193–354) 87 183.2 (109–269)  128 <0.0001
d-dimer (ng/mL) (max) 1,768 (967–4,262) 78 1,916.0 (1,172–4,689)  124 0.24
Platelet count (103/mm3) (minimum values  
observed during the first 7 d in ICU)
167 (131–208) 87 185 (136–238)  128 0.16
Creatinine (mg/dL) (max) 1.46 (1.01–2.36) 87 1.14 (0.89–1.75)  128 0.0053
Bilirubine (mg/dL) (max) 1.16 (0.75–1.90) 87 0.85 (0.68–1.20) 128 0.0007
COVID-19 = coronavirus disease 2019, HFNO = high-flow nasal oxygen, LOS = length of stay, max = maximum values observed during 
the first 7 d in ICU, MV = mechanical ventilation.
Quantitative variables are reported as median (Q1–Q3) and categorical variables as number (%). Kruskal-Wallis and Fisher exact tests 
are used as appropriate.
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less frequent and shorter. Finally, patients were antici-
patively transferred to other hospitals to mitigate crit-
ical care burden.
In this study, most of the W2 patients were already 
treated by dexamethasone on ICU admission. Steroid 
use can explain the lower CRP values during ICU stay 
and the lower d-dimer values on ICU admission. This 
latter biomarker has been linked to severity of acute 
respiratory distress syndrome (ARDS) (17). Another 
marker of severity, SOFA score, was also lower in W2 
patients, because they were frequently intubated later 
than the first day of ICU despite a lower Pao2/Fio2 
ratio due to wider use of HFNO. The use of organ sup-
ports was less frequent in W2 patients, but this change 
did not translate into a lower mortality rate during W2 
in the multivariate analysis.
TABLE 4. 
Risk Factors for 30-d Mortality of Hospitalized Coronavirus Disease 2019 Patients During 
the First and Second Waves of the Coronavirus Disease 2019 Pandemic
Parameter n
Univariate Multivariate (n = 960)
HR (95% CI) pa HR (95% CI) p
Wave (s) 1,003 0.75 (0.56–1.02) 0.066 0.69 (0.51–0.94) 0.019
Age (yr) 1,003 1.06 (1.05–1.08) <0.0001 1.08 (1.06–1.09) <0.0001
Body mass index (kg/m2) 766 0.99 (0.96–1.02) 0.43   
Gender (male) 1,003 1.28 (0.93–1.75) 0.13   
Chronic kidney disease (yes) 1,003 1.67 (1.15–2.43) 0.0069   
Diabetes (yes) 1,003 0.81 (0.60–1.103) 0.18   
Hypertension (yes) 1,003 1.33 (0.98–1.81) 0.070   
Total bilirubin on hospital admission (mg/dL, Ln) 976 1.06 (0.82–1.36) 0.68   
C-reactive protein on hospital admission (mg/L) 984 1.002 (1.0001–1.003) 0.053 1.002 (1.001–1.004) 0.0064
Creatinine on hospital admission (mg/dL, Ln) 982 1.68 (1.32–2.13) <0.0001 1.87 (1.39–2.50) <0.0001
d-dimers on hospital admission (µg/L, Ln) 849 1.20 (1.04–1.38) 0.012   
Procalcitonin on hospital admission (µg/L, Ln) 847 1.32 (1.20–1.45) <0.0001   
Ferritin on hospital admission (µg/L, Ln) 266 1.30 (0.99–1.69) 0.053   
Fibrinogen on hospital admission (g/L) 965 0.93 (0.85–1.01) 0.098   
Lactate dehydrogenase on hospital admission 
(U/L, Ln)
927 1.95 (1.40–2.71) <0.0001   
Lymphocyte count on hospital admission  
(103/mm3, Ln)
981 0.75 (0.58–0.97) 0.027   
Platelet count on hospital admission (103/mm3, Ln) 981 0.71 (0.50–0.99) 0.044 0.68 (0.48–0.97) 0.033
Oxygen saturation on hospital admission (%) 998 0.98 (0.96–0.99) 0.0010 0.97 (0.95–0.98) <0.0001
Respiratory frequency on hospital admission  
(beats/min, Ln)
900 1.82 (1.25–2.66) 0.0018   
Heart rate on hospital admission (beats/min, Ln) 1,003 1.002(0.99–1.01) 0.70   
Mean arterial pressure on hospital admission  
(mm Hg, Ln)
1,003 0.99 (0.98–0.995) 0.0031   
Temperature on hospital admission (°C, Ln) 991 0.89 (0.74–1.08) 0.24   
HR = hazard ratio, Ln = Neperian logarithm.
Cox regression models are used to assess risk factors of mortality. All the variables with p < 0.1 were selected for the multivariate model.
aAdjusted for wave.
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There are few studies comparing management 
strategy during COVID-19 pandemic (18). Contou et 
al (19) compared patient management and outcome in 
ICU patients during W1 and W2, where early steroid 
use featured in W2 was minimal in W1. In addition, 
they gave intermediate or full dose of thromboprophy-
laxis in half of the patients during W1 and all patients 
during W2. Unlike this study, they did not use anti-
viral treatment. Their main changes between W1 and 
W2 were associated with an increase in the delay be-
tween ICU admission and intubation, a decrease in 
the number of patients requiring MV, a decrease in 
the number of thrombotic events, and a decrease in 
d-dimer values. However, they did not observe a de-
crease in the ICU length of stay, duration of MV, RRT, 
antibiotic use, or vasopressor support. Furthermore, 
although SOFA score and patient age were similar to 
our present study, their proportion of mechanically 
ventilated and RRT patients was higher, which may 
explain their higher mortality rate. However, in both 
studies, ICU mortality did not decrease between the 
two periods, despite a decrease in d-dimer values.
Dennis et al (20) measured temporal survival trends 
in COVID-19 patients requiring critical care. From 
March 1 to June 27, 2020, they observed that 30-day 
ICU survival increased markedly over the study from 
58% to 84%, attributing changes to the introduction 
of effective treatments as part of the Recovery study, 
improved physician understanding of the disease pro-
cess, and falling critical care burden. Similarly, Bravata et 
TABLE 5. 
Risk Factors for 30-d Mortality of ICU Cornavirus Disease 2019 Patients During the First 
and second Waves of the Cornavirus Disease 2019 pandemic
Variables n
Univariate Multivariate (n = 199)
HR (95% CI) pa HR (95% CI) p
Wave (s) 215 1.03 (0.61–1.75) 0.91 0.68 (0.37–1.24) 0.21
Age (yr) 215 1.06 (1.03–1.10) 0.0001 1.06 (1.03–1.10) 0.0004
Body mass index (kg/m2) 197 0.99 (0.95–1.05) 0.97   
Gender (male) 215 1.37 (0.73–2.55) 0.33   
Chronic kidney disease (yes) 215 1.80 (1.03–3.16) 0.040   
Diabetes (yes) 215 0.79 (0.46–1.33) 0.37   
Hypertension (yes) 215 1.03 (0.59–1.80) 0.91   
Sequential Organ Failure Assessment on ICU admission 205 1.13 (1.05–1.21) 0.0007 1.13 (1.03–1.25) 0.0083
Pao2/Fio2 on ICU admission (mm Hg, Ln) 133 0.64 (0.27–1.53) 0.32   
Mean arterial pressure on ICU admission (mm Hg) 215 0.96 (0.94–0.98) 0.0007   
Lymphocytes on ICU admission (103/mm3, Ln) 212 0.57 (0.40–0.83) 0.0033 0.57 (0.38–0.85) 0.0057
C-reactive protein on ICU admission (mg/L) 213 1.00 (0.99–1.003) 0.73   
d-dimers on ICU admission (µg/L, Ln) 185 1.05 (0.80–1.37) 0.73   
Creatinine on ICU admission (mg/dL, Ln) 213 1.40 (0.96–2.04) 0.085   
Total bilirubin on ICU admission (mg/dL, Ln) 212 0.90 (0.58–1.42) 0.66   
Platelet count on ICU admission (103/mm3, Ln) 213 0.60 (0.36–1.004) 0.052   
Ferritin on ICU admission (µg/L, Ln) 123 1.12 (0.82–1.55) 0.47   
Troponin on ICU admission (ng/L, Ln) 209 1.26 (1.12–1.43) 0.0003   
HR = hazard ratio, Ln = Neperian logarithm.
Cox regression models are used to assess risk factors of mortality. All the variables with p < 0.1 were selected for the multivariate model.
aAdjusted for wave.
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al (21) examined whether COVID-19 mortality among 
patients in the general ward was associated with ICU 
strain. Hospital mortality varied over time from 25% 
to 12.5% according to strains on critical care capacity. 
COVID-19 ICU demand was associated with increased 
mortality for patients with critical COVID-19, support-
ing the idea strained critical care capacity was associ-
ated with increased COVID-19 ICU mortality.
Evidence-driven modification of our global patient 
management strategy between W1 and W2 decreased 
hospital, but not ICU, mortality. This result is explained, 
in part, by preventing degradation of COVID-19 
patients, thus reducing the need for ICU. Indeed, the 
ICU mortality rate of W1 and W2 patients was the 
same as patients with non-COVID-19–induced ARDS 
(22). However, mortality is not the only outcome to be 
considered. In this pandemic, the use of critical care 
resources and long-term physical and functional out-
comes of survivors must also be considered. Any de-
crease in ICU admission, MV duration, and length of 
stay reduces local overcrowding and may, therefore, 
improve the quality of care (16). It is anticipated that 
less RRT, shorter ICU length of stay, and shorter MV 
duration decrease the need of post ICU rehabilitation, 
the occurrence of post ICU syndrome, and therefore 
facilitate fast recovery of the patients.
The main limitation of this study is its single-center 
design. However, the sample size was large, and this sin-
gle-center design was able to ensure good homogeneity 
in patient management during the two periods of the 
study. The single-center prospective design of the study 
also resulted in few missing data thanks to the electronic 
medical file used in our hospital. Finally, while only a 
single center, the changes in patient care were evidence-
driven and relatively binary in the significant increase 
or decrease in use of a treatment approach (e.g., steroid 
use) between the waves. Thus, the present results would 
be very likely to generalize and transfer to other centers. 
Another limitation is the lack of data about the number 
of patients who were not admitted in ICU during both 
waves due to poor prognosis. However, our triage deci-
sions did not change with time, so we could expect this 
did not influence the present results.
CONCLUSIONS
In a single tertiary hospital, the main therapeutic 
changes between W1 and W2 of the COVID-19 
pandemic were eliminating use of hydroxychloro-
quine, use of remdesivir for patients under oxygen 
support and sick for less than 5 days, early use of 
steroids for hypoxemic patients including patients 
under MV, unrestrictive use of HFNO for hypox-
emic patients, and transfer of patients to other ge-
ographical areas in case of overcrowding. These 
changes were associated with a decrease in 30-day 
mortality, ICU admission, length of ICU stay, and 
organ support.
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